Blog
RSS FeedPosted by Michael Wonder on 18 Aug 2016
Cancer drug appraisal needs to be reviewed
18 August 2016 - ABPI Executive pens letter to The Guardian. ...
Posted by Michael Wonder on 18 Aug 2016
NICE recommends crizotinib, first pill for lung cancer
18 August 2016 - New draft guidance from NICE means hundreds of people will now have access to crizotinib, a twice-a-day ...
Posted by Michael Wonder on 17 Aug 2016
Promise and plausibility: health technology adoption decisions with limited evidence
18 August 2016 - The adoption of new medical devices and diagnostics is often hampered by lack of published evidence which ...
Posted by Michael Wonder on 17 Aug 2016
UK patient groups urge government to negotiate drug prices
16 August 2016 - Arguing that cancer patients in the United Kingdom are missing out on new treatments, two leading charities ...
Posted by Michael Wonder on 15 Aug 2016
ABPI responds to the International Comparisons of Health Technology Assessment report and claims that patients are being denied life-prolonging treatments
15 August 2016 - The Association of the British Pharmaceuticals Industry has responded to the International Comparisons of Health Technology Assessment ...
Posted by Michael Wonder on 15 Aug 2016
NHS patients missing out on cancer drugs
15 August 2016 - Thousands of NHS patients in the UK are missing out on access to innovative treatments that are ...
Posted by Michael Wonder on 12 Aug 2016
Thousands to benefit as NICE set to recommend drug to prevent heart attacks and strokes
12 August 2016 - NICE has published draft guidance recommending anti-clotting drug ticagrelor 60 mg with aspirin for people who have ...
Posted by Michael Wonder on 11 Aug 2016
A novel UK approach to cancer access: yes, no, or maybe?
10 August 2016 - What are the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients? ...
Posted by Michael Wonder on 10 Aug 2016
Cancer patients may lose vital drug in crackdown on funding: watchdog reviews 31 treatments that are not usually available on the NHS
10 August 2016 - The drug brentuximab vedotin may no longer be provided on the NHS. ...
Posted by Michael Wonder on 09 Aug 2016
NICE issues draft guidance on the use of talimogene laherparepvec
9 August 2016 - Talimogene laherparepvec (Imlygic) is the first cellular therapy to be appraised by NICE. ...
Posted by Michael Wonder on 04 Aug 2016
NICE issues draft guidance on the use of lesinurad
3 August 2016 - NICE has issued draft guidance on the use of lesinurad (Zurampic) for the treatment of patients ...
Posted by Michael Wonder on 04 Aug 2016
NICE draft guidance recommends new drug for people with ankylosing spondylitis
4 August 2016 - New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have ...
Posted by Michael Wonder on 03 Aug 2016
NICE issues draft guidance on the use of Otezla (apremilast)
3 August 2016 - NICE has issued draft guidance on the use of apremilast for the treatment of patients with moderate ...
Posted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...
Posted by Michael Wonder on 01 Aug 2016
Make drug makers pay: England’s strategy for cancer medicines
29 July 2016 - Roche, Pfizer concerned new system has no spending limit. ...